Q3 2024 Bergenbio ASA Earnings Call TranscriptNov 13, 2024kr6.4 (-11.92%)Earnings- Q2 2024 Bergenbio ASA Earnings Call TranscriptAug 21, 2024kr11.7Earnings
- Q1 2024 Bergenbio ASA Earnings Call TranscriptMay 29, 2024kr14.28 (-0.97%)Earnings
- Q3 2023 Bergenbio ASA Earnings Call TranscriptNov 14, 2023kr18.14 (-3.41%)Earnings
- Q2 2023 Bergenbio ASA Earnings Call TranscriptAug 23, 2023kr10.88 (+13.10%)Earnings
- Q4 2022 Bergenbio ASA Earnings Call TranscriptFeb 16, 2023kr350.52Earnings
- Q3 2022 Bergenbio ASA Earnings Call TranscriptNov 15, 2022kr392.21 (-3.46%)Earnings
- Q2 2022 Bergenbio ASA Earnings Call TranscriptAug 23, 2022kr598.6 (-7.60%)Earnings
- Q1 2022 Bergenbio ASA Earnings Call TranscriptMay 24, 2022kr787.93 (-4.21%)Earnings
- Bergenbio ASA Strategy Update TranscriptMay 04, 2022
- Q4 2021 Bergenbio ASA Earnings Call TranscriptFeb 16, 2022kr864.26 (-4.50%)Earnings
- Q3 2021 Bergenbio ASA Earnings Call TranscriptNov 16, 2021kr1040.23 (+3.16%)Earnings
- Q2 2021 Bergenbio ASA Earnings Call TranscriptAug 17, 2021kr1130.92 (-5.41%)Earnings
- Q1 2021 Bergenbio ASA Earnings Call TranscriptMay 19, 2021kr1172.1 (-9.39%)Earnings
- Bergenbio ASA to Discuss Top Line Data From Phase II Trial Assessing Bemcentinib in Hospitalised COVID-19 Patients Call TranscriptMay 18, 2021
- Q4 2020 Bergenbio ASA Earnings Call TranscriptFeb 10, 2021kr1680.9 (-4.09%)Earnings
- Q3 2020 Bergenbio ASA Earnings Call TranscriptNov 17, 2020kr1408.59 (-3.60%)Earnings
- Q2 2020 Bergenbio ASA Earnings Call TranscriptAug 18, 2020kr1817.9Earnings
- Q1 2020 Bergenbio ASA Earnings Call TranscriptMay 19, 2020kr1998.69 (-7.01%)Earnings
- Q4 2019 Bergenbio ASA Earnings Call TranscriptFeb 11, 2020kr882.67Earnings
Q2 2022 Bergenbio ASA Earnings Call Transcript
Good morning, and welcome to the BerGenBio Second Quarter 2022 Report. I will just remind everyone about the formalities.
So what is BerGenBio about? We are entirely focused on the development of selective AXL inhibitors, in particular, the focus is on our lead compound bemcentinib, which is an oral, potent and highly selective inhibitor of the receptor tyrosine kinase AXL. We are developing bemcentinib in 2 specific indications, which are both significant in our opinion. First one being first-line non-small cell lung cancer STK11-mutated patients where we are preparing for a Phase Ib/IIa study in the second half of this year. And secondly, the hospitalized COVID-19 population, where we are engaging in a Phase IIb study across Europe. We are laser-focused to deliver value drivers in the next 12 to 18 months.
This is a highlight of our second quarter 2022. So in May of this year, we announced a focused strategy being the focus on development of bemcentinib in 2 significant indications, as I mentioned, the first line STK11-mutated non-small cell lung cancer
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
